EHVVF news CHILD-BRIGHT Network and Ehave Start Enrollment

New Post Public Reply Private Reply Replies (0) Message Board
i_like_bb_stock
98
EHVVF news CHILD-BRIGHT Network and Ehave Start Enrollment for Cognitive Rehabilitation Trial for Children with ADHD, Autism, and Congenital Heart Disease PR Newswire "Press Releases US - English"

OAKVILLE, Ontario , June 28, 2018 /PRNewswire/ --The CHILD- BRIGHT Network, a Canadian patient-oriented research network focussed on pediatric brain-based developmental disorders, and Ehave, Inc . (OTCQB: EHVVF), a healthcare company dedicated to empowering the mental health community with next-generation digital solutions, today announced the start of enrollment for the CHILD- BRIGHT Mega Team research project trial, a Canadian-developed video game-based cognitive intervention that aims to improve executive functions in children with brain-based developmental disabilities such as Attention Deficit and Hyperactivity Disorder (ADHD), Autism Spectrum Disorder (ASD), or born with a Congenital Heart Defect (CHD).

In Canada , as many as850,000children under the age of 14 are living with a brain-based developmental disability, many of whom struggle with executive functions such as self-regulation, attention, impulsivity, and academic efficiency and accuracy. CHILD- BRIGHT investigators at The Hospital for Sick Children ( SickKids ), with industry partner Ehave , have developed Mega Team, a series of innovative cognitive rehabilitation video games to improve executive functions

The clinical trial, led by Dr. Jennifer Crosbie , Associate Scientist in the SickKids Research Institute and Principal Investigator of the project within the CHILD- BRIGHT Network, will enroll 460 children between the ages of 6 and 12 with ADHD, ASD or CHD. Children will play a series of games that target response inhibition time and working memory. Via in-clinic assessments at the start and end of the trial, and again 3 months later, the research team will measure improvements in executive functions, attention and self-regulation.

"Currently, cognitive rehabilitation interventions geared to improving cognitive deficits associated with neurodevelopmental disorders place high demands on families for professional supervision, are expensive, and have minimal established impact on behavioural regulation," says Dr. Crosbie . "Our Mega Team game is innovative because it is a non-pharmacological intervention that is carried out at home, via an online gaming platform, and that requires very little trainer supervision. Because the game's platform is engaging, children are motivated to play."

Industry partner Ehave developed the mental health informatics solution Ehave Connect. The Ehave Connect platform efficiently and effectively captures data from intake to assessment to diagnosis to treatment plan to outcomes. It gives mental health clinicians and researchers a complete picture of their patients using tools they already rely upon and provides access to innovative solutions such as the CHILD- BRIGHT Mega Team game. Mega Team training is tracked on the platform, and outcomes are available to the researchers to visualize the performance over time.

"We feel there is strong clinical potential for the Mega Team game in children with ADHD, ASD and CHD," said Prateek Dwivedi , CEO of Ehave . "The trial with the CHILD- BRIGHT Network is an important step to validate the treatment impact of Mega Team with high-quality clinical rigour. It is only with this validation that clinicians, parents, and patients can feel confident in the efficacy and safety of our digital therapy as a drug-sparing or drug-reducing treatment option."

A pilot of the Mega Team project supported by the Ontario Brain Institute (OBI) and the Province of Ontario Neurodevelopmental (POND) Network was carried out in 2017 and provided initial evidence that game-based cognitive rehabilitation may be a promising intervention for executive function deficits.

CHILD- BRIGHT Mega Team enrollment information is available at www.child-bright.ca/megateam or by contacting the project coordinator at mega.team@sickkids.ca or 416-813-8210.

Project Funding Partners The CHILD- BRIGHT Mega Team project is funded by the CHILD- BRIGHT Network, under the Canadian Institutes of Health Research (CIHR) Strategy for Patient-Oriented Research (SPOR) initiative, with support from the SickKids Foundation . Early development work and pilot funding for the Mega Team project was funded by the Ontario Brain Institute (OBI), Province of Ontario Neurodevelopmental (POND) Network and in-kind support from industry partner Ehave . Dr. Crosbie is supported by the Susan Bradley Health Clinician Scientist Award in Child & Youth Mental Health and the O'Brien Scholar Program.

About the CHILD- BRIGHT Network The CHILD- BRIGHT Network, headquartered at the Research Institute of the McGill University Health Centre (RI-MUHC), is an innovative pan-Canadian network that aims to improve life outcomes for children with brain-based developmental disabilities and their families. Using child- and family-focused approaches, we work to create novel interventions to optimize development, promote health outcomes, and deliver responsive and supportive services. Co-Directed by investigators at the BC Children's Hospital and The Hospital for Sick Children ( SickKids ), CHILD- BRIGHT is made possible thanks to a five-year grant by the Canadian Institutes of Health Research (CIHR) under Canada's Strategy for Patient-Oriented Research (SPOR), and 27 generous funding partners from public and private sectors across Canada . www.child-bright.ca

About Ehave Ehave, Inc. (OTCQB: EHVVF) is empowering the mental healthcare community with a next generation of data-rich tools designed to improve patient management, diagnosis and treatment. With Ehave Connect, Ehave's mental health informatics platform, clinicians can make objective, data-driven decisions while keeping patients informed and engaged throughout their mental healthcare journey. Ehave Connect offers a powerful set of core features that integrate with a growing selection of tools and applications developed by Ehave and its leading partners, including Multi-Health Systems ("MHS" , a leading publisher of psychological assessments. Ehave is initially focused on improving the standard of care in attention deficit hyperactivity disorder ("ADHD" , through its collaboration with the Hospital for Sick Children (" SickKids " . Ehave Connect is also being utilized to advance the validation and optimization of medical cannabis, through its collaboration with leading medical cannabis licensed producers. www.ehave.com



View original content:http://www.prnewswire.com/news-releases/child-bright-network-and-ehave-start-enrollment-for-cognitive-rehabilitation-trial-for-children-with-adhd-autism-and-congenital-heart-disease-300673821.html

SOURCE Ehave, Inc.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

AppLovin Legal Woes: A Deep Dive into Investor Claims

Updated Category News Views 378

AppLovin Faces Legal Heat and Market Scrutiny Bitter truth has a way of crashing like a wave, and AppLovin (NASDAQ: APP) is feeling the brunt of it. Now knee-deep in a securities class action, the firm’s been accused of selling fairy tales about its AI capabilities, leaving investors clutching at substantial losses. If you’ve been banking on their promises between...

Continue Reading
Webull Faces Class Action: Key Details for Investors

Updated Category News Views 340

What's Really Going on With Webull? When you hear there's a class-action lawsuit brewing, you know something's gone real sideways. Webull Corporation (NASDAQ: BULL) finds itself neck-deep in a securities fraud class action alleging some dicey dealings with China. If you've got skin in the game—and if you bought Webull stock between April 26, 2025, and October 6,...

Continue Reading
JOYEE N01 Debuts Globally with First 2,000 Deliveries

Updated Category News Views 63

JOYYE N01 Breaks into the Global Market Now, here we go, folks—a Chinese car with ambitions bigger than the Sahara. On October 28, the JOYEE N01 rolled off the assembly line and into the international scene with a lot of fanfare at FAW's Yancheng Branch. Mark my words, this isn't just another model trying to strut into the global auto arena. This event delivered the...

Continue Reading
Shenzhen's Vision Unveiled: APEC 2026 Promo Debut

Updated Category News Views 247

Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...

Continue Reading
YSTUDIO's Pens: A Nod to the Power of Writing

Updated Category News Views 505

Slow Down, Write On: A New Era for Stationery In a world where sentiments zip around with a swipe, here we find YSTUDIO tapping into something analog and profound. Their latest offerings—a 'Brand Day Gift Box' and the 'Inner Universe' pen series—are more than just high-end stationery. They’re an invitation to reconnect with the written word, a gesture to slow our...

Continue Reading
WeaveGrid Powers EVConnectNC: Charging Incentives Launched

Updated Category News Views 262

Transforming Utilities with EVConnectNC In a fresh move by WeaveGrid, North Carolina's Electric Cooperatives have teamed up to roll out EVConnectNC. This innovative program aims to manage the burgeoning demand for electric vehicle (EV) charging in rural and suburban areas under North Carolina's cooperative umbrella. Think of it as a smart way to handle new loads without...

Continue Reading
Novo's CagriSema Trial Shows Promising Obesity Results

Updated Category News Views 425

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 48

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
PASCAL's Holiday Gift Edit: Timeless Watches Shine

Updated Category News Views 456

Fresh Sparkle for the Holidays Well, here we are again, staring down the barrel of another holiday season. And what do you know, PASCAL is out with its 2026 Holiday Gift Edit, like clockwork. This is the kind of stuff they’re good at—capturing a moment, slapping some color on it, and calling it a game-changer. Launching on November 14, this edit nods to their Timeless...

Continue Reading
Servier's Data on Tovorafenib Shows Promise in pLGG

Updated Category News Views 468

New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...

Continue Reading

Top 5 Most Recently Viewed Articles

C3is Inc (CISS) Hits 52-Week Low; Analyzing Market Challenges

Updated Category News Views 210

C3is Inc (CISS) hit a new low recently, dropping to $1.09 a share. This marks a staggering 97.53% decline over the past year, leaving investors scratching their heads about where this company is headed next. C3is Inc: A Company in Crisis As the stock tumbles to its 52-week low, the implications for C3is's market position are glaring. With a market cap of just $6.75...

Continue Reading
Securitas AB Set to Release Q3 2025 Financial Results Soon

Updated Category News Views 308

Securitas AB Announces Release of Q3 2025 Results STOCKHOLM, Oct. 29, 2025 - Securitas AB is gearing up to publish its Interim Report for the period of January to September 2025 on Thursday, November 6, 2025, at 8:00 a.m. CET. This important financial document will provide insights into the company's performance and outlook for the future. Details of the Report Release...

Continue Reading
XRP Whales Drive Demand for ExoraPad's $EXP as Presale Surges

Updated Category News Views 216

XRP Whales Drive Demand for ExoraPad's $EXP as Presale Surges In a remarkable show of confidence, XRP whales are actively positioning themselves to acquire ExoraPad's $EXP tokens, resulting in a presale that has quickly exceeded expectations. This impressive feat has occurred just hours after the presale launch, where over 30% of the softcap has already been raised,...

Continue Reading
Innovative Partnership for Elderly Services and Board Changes

Updated Category News Views 164

Strengthening Services for the Elderly CLIK is thrilled to announce its exciting new partnership with Flash Mutual, a cutting-edge technology firm operating under Tencent's Sustainable Social Value initiatives. This collaboration is designed to deliver round-the-clock instant device services specifically aimed at enhancing the lives of senior citizens. A Focus on...

Continue Reading
Microsoft's Fourth-Quarter Forecast: Anticipating Growth and Innovation

Updated Category News Views 217

Overview of Microsoft's Upcoming Fourth Quarter Earnings Microsoft Corporation (NASDAQ: MSFT) is positioning itself for a robust financial report as it gears up to share its fourth-quarter results. Analysts are excited about the anticipated growth driven by advancements in AI and cloud services, highlighting the company's impressive trajectory in the tech sphere. Earnings...

Continue Reading